• In March 2026, Alteogen announced an exclusive license deal giving Biogen rights to develop subcutaneous formulations for two biologic products using ALT-B4 Hybrozyme technology, while new data from Eisai and Biogen showed strong long-term real-world treatment persistence for intravenous lecanemab in Alzheimer’s patients.
• Together, these developments highlight Biogen’s push to expand patient-friendly biologic delivery and deepen its presence in Alzheimer’s care through therapies patients are continuing over time.
• We’ll now look at how Biogen’s ALT-B4 subcutaneous biologics deal could reshape its existing investment narrative around growth and risk.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

Biogen Investment Narrative Recap

To own Biogen today, you generally need to believe that new neurology and rare-disease drugs can offset pressure on legacy multiple sclerosis brands and that Alzheimer’s therapies become meaningful, durable franchises. The Alteogen ALT-B4 deal fits that view by broadening Biogen’s tools for subcutaneous biologics, while the real-world lecanemab persistence data goes right to the heart of the Alzheimer’s catalyst, though it does not remove the company’s reliance on a few key launches.

The most relevant recent announcement here is the Eisai and Biogen update on long-term lecanemab use, showing most patients stayed on intravenous treatment beyond 18 months. For an investment case that already leans heavily on lecanemab, these adherence data sit alongside Biogen’s move into ALT-B4-enabled subcutaneous delivery as part of the same question: whether Alzheimer’s can evolve from a high-risk pipeline story into a more predictable, treatment-persistence-driven pillar of the business.

Yet against this potential, investors still need to weigh issues such as legal overhangs and pricing pressure that could limit how much of this progress ultimately reaches...

Biogen's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2028.

Uncover how Biogen's forecasts yield a $205.67 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Compared with the consensus story, the most pessimistic analysts saw Biogen’s revenue sliding to about US$8.6 billion and still question whether lecanemab and convenience upgrades like subcutaneous options can overcome pricing pressure and access hurdles, so it is worth remembering that informed views on this stock vary widely and may shift again as the Alteogen deal and new Alzheimer’s data are fully absorbed.

Explore 7 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.